Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide.

D.V.P. Almeida, C.Z. de Oliveira, R.C. Mariano, F.R. Kater, M.C.L.A. Souza, V.C. RuizSchutz, R. Yamamura, R. Saraiva De Carvalho, F.C. Maluf, A.K. Morgans, S. Srinivas, S. Gupta, T. Dorff, E.Y. Yu, F.A. Schutz Medical Oncology, BP A Beneficência Portuguesa de S~ao Paulo, S~ao Paulo, Brazil, Biostatistcs, BP A Beneficência Portuguesa de S~ao Paulo, S~ao Paulo, Brazil, Internal Medicine, Universidade de S~ao Paulo, S~ao Paulo, Brazil, Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Department: Medicine Med/ Oncology, Stanford University, Stanford, CA, USA, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA, Medical Oncology, City of Hope, Duarte, CA, USA, Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA